Researchers concluded that the test, which required less than 5 minutes of user hands-on time, provided accurate organism identification and detection of resistance Staphylococcus aureus or S. epidermidis. Researchers concluded that the test, which required less than 5 minutes of user hands-on time, provided accurate organism identification and detection of resistance genes compared to routine laboratory methods.
http://www.nanosphere.us/
Nanostart Asia Pacific is preparing an additional fundraising of up to 4 million SGD for its further expansion. A large part of the amount has already been committed. As in the previous funding in February 2012, the money comes from the existing shareholders and new investors based in the region. It shall be used for follow up funding the existing portfolio. Furthermore Nanostart Asia Pacific is already working on new investment opportunities.
In addition the company has formed an advisory board with renowned experts in order to support the further development of the company. The board will initially comprise of Harry De Wit, President Asia with Covidien, Prof. Dr. Uwe Klima, Head of Cardiosurgery at the American Hospital Dubai, Günter Mayer, Senior Manager with Infineon, Jürgen Binzer, Entrepreneur and Vice President with Hollingsworth & Vose in Germany and Chua Hong Moh, Entrepre- neur from Singapore. The advisors will support the company’s further development and its expansion in Asia by providing their expertise as well as their broad network.
The announcement is made during the event "Investing in Singapore Nanotechnology" at Singapore Polytechnic, where Nanostart Asia Pacific and Sin- gapore Polytechnic jointly feature their activities in the nano- and high-tech space to the investment and business community.
Nanostart-holding ItN Nanovation AG has successfully completed the capital increase announced on September 12. By placing 838,964 new shares among existing shareholders, a net value of nearly 1.2 million euros will flow into the company. The issue price was determined in direct juxtaposition to the stock market price, as the legal right to purchase was excluded. The capital increase raises the share capital of ItN Nanovation to 11,832,766 euros. The incoming funds will serve to strengthen the equity capital of the company.
http.//
www.itn-nanovation.de http://nanostart.de/
NanoString Technologies, Inc., has obtained the CE Mark for its PAM50-based gene expression test for breast cancer, clearing the company to sell its test in the European Union and other countries recognizing the CE Mark. NanoString’s test provides a subtype classification based on the fundamental biology of an individual’s breast tumor (referred to as intrinsic subtyping), as well as a prognostic score that predicts the probability of cancer recurrence over 10 years in post-menopausal women with hormone receptor-positive, early stage breast cancer (ESBC) who have been treated with hormonal therapy.
http://www.NanoString.com http://www.nanostart.de
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93